Professor Raoult mandates lawyer di Vizio to lodge an appeal with the Council of State and a criminal complaint after the refusal of the Medicines Agency to authorize hydroxychloroquine more widely
Didier Raoult and the IHU will contest the refusal of the National Medicines Safety Agency (ANSM) to authorize the use of hydroxychloroquine against Covid-19. Mandated by the IHU, lawyer Di Vizio sent a request for annulment on Thursday to the Council of State in accordance with the possibility given by such a decision. In addition, a complaint against the agency and its director Dominique Martin for endangering the life of others will be filed on Friday.
Since the start of the pandemic, Professor Raoult has treated more than 4,000 patients with dual therapy hydroxychloroquine + azithromycin supplemented with zinc. In addition, he was a promoter of the Identify, Test, Isolate, Treat approach which has earned the IHU the lowest mortality rate in France. Several of the studies promoted by the IHU and its professors did not receive the same degree of attention in the media, or received vile attacks from certain colleagues because, according to them, these studies did not respect the methodology considered as the rule of law. gold in Evidence Based Medicine. Professor Raoult defends himself by explaining that in the context of an epidemic, everyone must be treated and it would be immoral to offer a placebo to a patient.
In addition, Professor Raoult criticizes the health authorities for not having reserved the same treatment with hydroxychloroquine as with Gilead’s remdesivir, going so far as to favor the latter drug.
In its decision to refuse RTU dated 23 October 2020, the ANSM indicated that the available data do not suggest a benefit from hydroxychloroquine, alone or in combination, for the treatment or prevention of Covid-19 disease.
The same treatment was not reserved for remdesivir, which is a toxic and ineffective product. Numerous links and possible conflicts of interest between the health authorities, certain doctors and Gilead, will be at the center of the investigations that will not fail to expedite the criminal judge. It should also be remembered that Professor Lina said in his hearing in the Senate that despite the weakness of the efficacy signals, remdesivir was included in the Discovery study in order to prevent patients from losing their chances.
Remdesivir has no significant effect
In France, remdesivir benefits from a cohort temporary authorization for use (ATU) which allows certain categories of patients to receive drugs that have not yet been placed on the market. “To date, the drug has not proven its effectiveness on 14-day mortality, said the High Authority for Health, which had requested additional data on the studies to meet the demand for reimbursement of the drug. Request which has since been withdrawn by Gilead. In addition, this drug did not prove any benefit in the Solidarity study, which resulted in a violent response from Gilead. Response to which Ms. Kieny from INSERM responded.
To defend itself, the ANSM does not recommend the massive use of remdesivir, however a recent communication from the Ministry of Health looked a lot like a “sale with liquidation of stocks before closures”
The toxicity of remdesivir is not unknown in the medical community since a recent study carried out at Bichat Hospital on four of the five patients hospitalized and treated with remdesivir had side effects causing the treatment to be stopped.
During her hearing by the parliamentary commission of inquiry on June 25, Karine Lacombe said ” cannot believe that in such an exceptional health situation, there was on the part of the Scientific Council, the High Health Authority or the Medicines Agency a desire to slow down the arrival on the market of medicines, simply because there was a laboratory, however powerful it might be ”which would have exerted pressure. She is among the many doctors to receive favors from pharmaceutical companies (212,000 euros declared in EuroForDocs) and occupies third place in the top 12 of the ranking published in June 2020.
For his part, Dr Yazdanpanah, director of Reacting, recently said on television that remdesivir is unlikely to be effective. And INSERM’s Ms. Kieny says it’s a “huge” waste for EU countries to invest in remdesivir on the premise that it might help a small subset of patients. “You can always say, OK, now if I separate the population and just take the ones with a blue eye and a wooden leg, maybe that’s very effective,” she says.
Remember that remdesivir obtained an agreement from the FDA (American Medicines Agency) on October 22, which was strongly contested by an article in ScienceMag.
Note that this October 28, Gilead had a full page of advertising on the elimination of hepatitis C next to an article on the invitation of justice in the management of the Covid in the Parisian.
Gilead was also the subject of a thorough investigation by the site armswatch.com as part of its drug Sovaldi against hepatitis C
In Georgia, there were reportedly a cover-up of deaths in a $ 3.3 billion drug project. Confidential reports reveal that at least 249 patients enrolled in a Gilead-sponsored program have died in Georgia. New data breach reveals Georgian government and US giant Gilead have not investigated at least 249 deaths patients enrolled in a project to eliminate $ 3.3 billion hepatitis C. Arms Watch analyzed the documents which were said to have originated from the Georgia Ministry of Health and were disclosed anonymously on Twitter. A detailed report has already been published on US government plans at the Pentagon’s biolab in Tbilisi – the Lugar Center.
In the current report, the data on patent deaths registered in the hepatitis C elimination project in Georgia was analyzed. This is an experimental pharmaceutical project sponsored by Gilead in cooperation with the US Centers for Disease Control (CDC) and the Georgia Department of Health.
Georgian media and health officials have previously denied any possible connection between the experimental program and these death cases. However, the cause of death for some patients has been reported as “unknown” in confidential Gilead reports. Other patients enrolled in the program discontinued treatment due to serious side effects. Some of them died.
In addition, $ 181.7 million in hepatitis C antivirals for 2,033 patients in Georgia went unused and expired due to “drug cancellations, patient deaths or other reasons. ”, According to these leaked documents.
Internal correspondence between Georgia, Gilead and the US Embassy in Tbilisi reveals that patients involved in the hepatitis C program have died and the treatment of others has been canceled.
Deaths of patients on hepatitis C treatment in the United States
The Institute for Safe Medication Practices (ISMP), a United States-based independent watchdog organization entirely dedicated to preventing medication errors, has previously reported serious safety concerns with the same Gilead Harvoni and Sovaldi drugs as those donated. to Georgia. The independent watchdog provided the exam following drug safety issues reflected in adverse events reported to the US Food and Drug Administration (FDA):
Reactivation of hepatitis B. In October 2016, the FDA identified the first major new safety issue related to the nine new direct-acting antiviral drugs for hepatitis C. For patients who currently or previously had an infection with the hepatitis B virus, the Antivirals can reactivate the virus and cause serious liver problems or death. The FDA report describes 24 cases of hepatitis B reactivation, including 3 cases of acute liver failure resulting in 2 deaths and 1 liver transplant. Hepatitis B reactivation was not detected in pre-approval clinical testing because these patients were excluded from the studies. This risk can potentially be managed through pre-treatment virologic testing for hepatitis B, as the FDA now recommends.
Liver damage and liver failure. Looking beyond the cases cited by the FDA above to examine the most recent 12 months of data up to Q2 2016 in the FDA cing system (FAERS), we identified 524 reported cases of insufficiency. hepatic associated drugs, and 1058 other reports of serious liver damage. which apparently did not progress to liver failure. The 524 reported cases of hepatic failure included all direct-acting antivirals approved as suspected primary or secondary drugs (Table 1), often in combination with each other or with ribavirin. Almost half of the cases reported encephalopathy, the hallmark symptom of liver failure. Generally, 165 (31.5%) had died at the time of the report. Although complications from hepatitis C rather than the suspect drug may have contributed to some cases, 90% of the reports were submitted by healthcare professionals, who would be more likely to understand the natural progression of the disease.
Not only local health officials have offered US pharmaceutical giant Gilead to freely test its investigational drug COVID-19 in Georgia, but they also exempted American diplomats from the quarantine inspection upon arrival in the country at the request of the American embassy in Tbilisi.
Amid the COVID-19 pandemic, the US Embassy in Tbilisi has not requested any inspections of US diplomats and their families, even though strict quarantine law requires all passengers upon arrival in the country. In response, Tamar Gabunia, Georgia’s first deputy health minister, informed the US embassy that the government had passed a special amendment granting an exemption to diplomats at the request of the US embassy.
It should be noted again that, in accordance with the US-Georgia Defense Cooperation Agreement, US civilian personnel working at the Lugar center were also granted diplomatic immunity, although they were not diplomatic.
American scientists working at the Lugar Center cannot be held accountable for their activities in Georgia since they have diplomatic status. Gilead also cannot be held accountable under the 2015 Gilead-Georgia MOU. The US pharmaceutical company has used Georgia as a free drug test bed for its products, which begs the question. find out why the Georgian authorities put the interests of a foreign government and a foreign company ahead of the interests of its own people.
Report from the investigation by Dilyana Gaytandzhieva who is a Bulgarian investigative journalist, Middle East correspondent and founder of Arms Watch. Over the past two years, she has published a series of revealing reports on arms deliveries to terrorists in Syria, Iraq and Yemen. His current work focuses on documenting war crimes and illicit arms exports to war zones around the world.